Tags

Type your tag names separated by a space and hit enter

Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
Rheumatology (Oxford). 2003 Feb; 42(2):321-5.R

Abstract

OBJECTIVE

To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout.

METHODS

Ten male patients (38-74 yr) with a history of chronic tophaceous or recurrent acute gout with hyperuricaemia and on established allopurinol at 300-900 mg/day for > or =3 months were studied in an open-crossover study of fenofibrate therapy. Allopurinol at the established dose was continued throughout the study. Clinical and biochemical assessments (serum urate and creatinine, 24-h urinary excretion of urate and creatinine, liver function tests, creatine kinase and fasting serum lipids) were undertaken at: (i) baseline, (ii) after 3 weeks of once-daily therapy with micronized fenofibrate (Lipantil Micro) at 200 mg and (iii) 3 weeks after fenofibrate was withdrawn.

RESULTS

Fenofibrate was associated with a 19% reduction in serum urate after 3 weeks of treatment (mean+/-S.E. 0.37+/-0.04 vs 0.30+/-0.02 mM/l; P=0.004). The effect was reversed after a 3-week fenofibrate withdrawal period (0.30+/-0.02 vs 0.38+/-0.03 mM/l). There was a rise in uric acid clearance with fenofibrate treatment of 36% (7.2+/-0.9 vs 11.4+/-1.6 ml/min, normal range 6-11; P=0.006) without a significant change in creatinine clearance. Both total cholesterol and serum triglycerides were also reduced. No patient developed acute gout whilst taking fenofibrate.

CONCLUSIONS

Fenofibrate has a rapid and reversible urate-lowering effect in patients with hyperuricaemia and gout on established allopurinol prophylaxis. Fenofibrate may be a potential new treatment for hyperuricaemia and the prevention of gout, particularly in patients with coexisting hyperlipidaemia or those resistant to conventional therapy for hyperuricaemia.

Authors+Show Affiliations

Lipid Clinic, London SW10 9NH, UK. m.feher@chelwest.nhs.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

12595630

Citation

Feher, M D., et al. "Fenofibrate Enhances Urate Reduction in Men Treated With Allopurinol for Hyperuricaemia and Gout." Rheumatology (Oxford, England), vol. 42, no. 2, 2003, pp. 321-5.
Feher MD, Hepburn AL, Hogarth MB, et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford). 2003;42(2):321-5.
Feher, M. D., Hepburn, A. L., Hogarth, M. B., Ball, S. G., & Kaye, S. A. (2003). Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford, England), 42(2), 321-5.
Feher MD, et al. Fenofibrate Enhances Urate Reduction in Men Treated With Allopurinol for Hyperuricaemia and Gout. Rheumatology (Oxford). 2003;42(2):321-5. PubMed PMID: 12595630.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. AU - Feher,M D, AU - Hepburn,A L, AU - Hogarth,M B, AU - Ball,S G, AU - Kaye,S A, PY - 2003/2/22/pubmed PY - 2003/5/13/medline PY - 2003/2/22/entrez SP - 321 EP - 5 JF - Rheumatology (Oxford, England) JO - Rheumatology (Oxford) VL - 42 IS - 2 N2 - OBJECTIVE: To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout. METHODS: Ten male patients (38-74 yr) with a history of chronic tophaceous or recurrent acute gout with hyperuricaemia and on established allopurinol at 300-900 mg/day for > or =3 months were studied in an open-crossover study of fenofibrate therapy. Allopurinol at the established dose was continued throughout the study. Clinical and biochemical assessments (serum urate and creatinine, 24-h urinary excretion of urate and creatinine, liver function tests, creatine kinase and fasting serum lipids) were undertaken at: (i) baseline, (ii) after 3 weeks of once-daily therapy with micronized fenofibrate (Lipantil Micro) at 200 mg and (iii) 3 weeks after fenofibrate was withdrawn. RESULTS: Fenofibrate was associated with a 19% reduction in serum urate after 3 weeks of treatment (mean+/-S.E. 0.37+/-0.04 vs 0.30+/-0.02 mM/l; P=0.004). The effect was reversed after a 3-week fenofibrate withdrawal period (0.30+/-0.02 vs 0.38+/-0.03 mM/l). There was a rise in uric acid clearance with fenofibrate treatment of 36% (7.2+/-0.9 vs 11.4+/-1.6 ml/min, normal range 6-11; P=0.006) without a significant change in creatinine clearance. Both total cholesterol and serum triglycerides were also reduced. No patient developed acute gout whilst taking fenofibrate. CONCLUSIONS: Fenofibrate has a rapid and reversible urate-lowering effect in patients with hyperuricaemia and gout on established allopurinol prophylaxis. Fenofibrate may be a potential new treatment for hyperuricaemia and the prevention of gout, particularly in patients with coexisting hyperlipidaemia or those resistant to conventional therapy for hyperuricaemia. SN - 1462-0324 UR - https://www.unboundmedicine.com/medline/citation/12595630/Fenofibrate_enhances_urate_reduction_in_men_treated_with_allopurinol_for_hyperuricaemia_and_gout_ L2 - https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/keg103 DB - PRIME DP - Unbound Medicine ER -